Avid Bioservices (CDMO)
(Delayed Data from NSDQ)
$11.93 USD
-0.27 (-2.21%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $11.85 -0.08 (-0.67%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
CDMO 11.93 -0.27(-2.21%)
Will CDMO be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CDMO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CDMO
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates
CDMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates
Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Lags Revenue Estimates
Avid Bioservices (CDMO) Reports Q2 Loss, Lags Revenue Estimates
Other News for CDMO
Avid Bioservices: Take-Private Deal At A Reasonable Price, Maintaining Buy
Hershey, Upwork And 3 Stocks To Watch Heading Into Thursday
Avid Bioservices just downgraded at Craig-Hallum, here's why
Avid Bioservices to be acquired for $1.1B in cash by GHO, Ampersand
Avid Bioservices downgraded to Sector Perform from Outperform at RBC Capital